Second-line therapy with Nal-IRI/5-FU/FA after failure of gemcitabine/nab-paclitaxel in advanced pancreatic cancer (PC): Predictive role of 1st-line therapy (PREDICT ...

Results from a post-hoc exploratory subgroup analysis from the NIAGARA Phase III trial showed AstraZeneca’s (AZN) IMFINZI, ...

Due to the ongoing shortage of BCG, gemcitabine has been increasingly used for first-line NMIBC therapy. N-803’s ability to activate natural killer and CD8+ T cells, thus the innate immune system, to ...

The 3-year local recurrence rate was 3.6% for transanal TME and 4.4% for laparoscopic TME. The 3-year overall survival was 92 ...

Researchers randomized patients with advanced neuroendocrine tumors 2:1 to receive either cabozantinib or placebo.

The following is a summary of “Efficacy of Zenocutuzumab in NRG1 Fusion–Positive Cancer,” published in the February 2025 ...

Type I interferon (IFN) score may effectively predict disease progression in limited cutaneous systemic sclerosis, with a ...

Bristol Myers Squibb said it is disappointed with the outcome of a study that examined whether one of its drugs could be used to treat a certain type of skin cancer. The drug, Opdualag, didn't meet ...

GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Fred Saad discussing a subgroup analysis of the phase 3 ARANOTE trial assessing darolutamide + ADT in patients with ...

Orca Bio announces it met the primary endpoint in its pivotal Phase 3 clinical study for its lead allogeneic T-cell immunotherapy, Orca-T.